– USA, NY – Y-mAbs Therapeutics, Inc., (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the nomination of healthcare executive Laura J. Hamill for election to its Board of Directors as a Class II director at the 2020 annual meeting of stockholders.
”We are pleased to welcome Ms. Hamill as a board member. Laura will add significant commercial experience to our board, which will be of great value to our plans to augment our commercial organization and bring our product candidates to patients,” said Thomas Gad, Founder, Chairman, President, Head of Business Development and Strategy of Y-mAbs.
Current member of the Board, Dr. Gregory Raskin, will retire from the Board at the end of his current term. He will continue to serve as a member of the Board until the Annual Meeting.
“On behalf of Y-mAbs’ board, shareholders and employees, I would like to recognize and thank Dr. Raskin for his great contributions to the successful development of Y-mAbs while serving on the Board,” added Thomas Gad.
Upon the expiration of Dr. Raskin’s current term at the Annual Meeting, the size of the Board will be maintained at eight directors. The other current Class II directors, James I. Healy, M.D., and Ashutosh Tyagi, M.D., whose terms expire at the Annual Meeting have informed the Board that they will stand for re-election to the Board at the Annual Meeting.
About Laura J. Hamill
Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue. There she led the global commercial strategic direction and long-term planning. As a member of the executive team, she contributed to the corporate strategy and overall governance of the organization. Over an 18-year career at Amgen, Ms. Hamill held a number of executive roles in the US and internationally. Her last role as Senior Vice President and General Manager included overall management of 2,000 employees, the strategic plans and $20 billion of annual revenue for U.S. Commercial Operations. Ms. Hamill’s areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI and anti-infectives.
Since September 2019, Ms. Hamill has served on the board of directors of AnaptysBio, Inc., a publicly-traded clinical-stage antibody-based biotechnology company. Ms. Hamill holds a B.A. in business administration from the University of Arizona.
About Y-mAbs
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.
For more information: https://ymabs.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
